AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01843894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RU-101
Description: Recombinant human serum albumin
Study NCT01843894 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RU-101
Description: Recombinant human serum albumin
Study NCT01028027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol and tobramycin
Description: Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
Study NCT01028027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin and dexamethasone
Description: Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
Study NCT02807103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1 g intravenous pulse at day1 and day15
Study NCT02807103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-rituximab
Description: intravenous pulses at day1 and day15
Study NCT02807103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
Study NCT02807103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-cyclophosphamide
Description: intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
Study NCT04034446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD22 CAR-T cells
Description: 0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.
Study NCT02811952 — intervention group
Intervention type: OTHER
Intervention: without intervention
Description: without intervention
Study NCT02112747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: Patients are randomized to receive the assistance of a patient navigator to understand, obtain assistance with following the screening recommendations of the personal prescription given to them by the website survey.
Study NCT01027182 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Raltegravir
Description: One 400mg tablet on day 1.
Study NCT01614431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
Study NCT01614431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: N acetyl cysteine for cystinosis patients CKD stages 1 to 4
Study NCT03576170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aromatherapy
Description: aromatherapy by inhalation and/or therapeutic massage
Study NCT02593266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive Intervention Program (PIP) for depression
Description: Manualized intervention designed by Beardslee and colleagues (Beardslee et al., 2003) It is a program based on cognitive behavioural therapy, narrative therapy and systemic therapy. It is divided in 7 modules which are imparted weekly in the family home by 2 'preventionists' (therapists trained to deliver the intervention)~* Module 1: Depression and family~* Module 2: Psychoeducation about depression~* Module 3:The child's perspective on their parent's depression~* Module 4: Skills development~* Module 5: Preparation for the family session~* Module 6: Family session~* Module 7: Revision and future planning~* Follow-up
Study NCT02534987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCPR2
Description: clinical decision support guiding clinician through clinical prediction rule and associated evidence based orders for strep and pneumonia
Study NCT01518933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin (Legalon-SIL)
Description: 20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
Study NCT01518933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT03383315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: One dose of intravenous tramadol 50mg
Study NCT03383315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: One dose of intravenous tramadol 50mg
Study NCT03383315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: One dose of intravenous metoclopramide 10mg
Study NCT03383315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9%
Study NCT03681847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: normal saline 0.9% 15 ml/kg over 15-20 minutes.
Study NCT03681847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyethyl starch
Description: hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
Study NCT03681847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: hypertonic saline 3% (7ml/kg) over 15-20 minutes.
Study NCT03503461 — intervention group
Intervention type: OTHER
Intervention: exosomes analysis
Description: Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.
Study NCT02279394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \& 15 Cycles 3-8
Study NCT02279394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg Oral; Days 1-21 days Cycles 1-24
Study NCT02279394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
Study NCT05717101 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT00979134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily
Study NCT00979134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Patients start at a dose of 80 mg twice daily, with no washout
Study NCT00979134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Single dose is followed by washout 5-10 days before multiple dose
Study NCT04007341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The study drug for each group was administered from the time immediately after induction of anesthesia until the end of the surgery.
Study NCT03218540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid management protocol
Description: SVV protocol: keep SVV 10-13% and give fluid when SVV > 13% CVP protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg
Study NCT03218540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid management protocol
Description: SVV protocol: keep SVV 10-13% and give fluid when SVV > 13% CVP protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg
Study NCT00080093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual feedback and specially-tailored manuals
Description: Individual feedback and specially-tailored manuals
Study NCT00080093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General HIV information feedback and the best-available information
Description: General HIV information feedback and the best-available information
Study NCT06031038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TECCU Software
Description: patient monitoring by software application
Study NCT03835429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyTAP oral appliance plus mouth shield
Description: The midline traction oral appliance (MyTAP, Airway Management Inc.(AMI), Dallas Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared.
Study NCT04026659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-modal exercise
Description: A combination of aerobic, resistance, balance and flexibility exercises will be included. Aerobic exercise will consist of 20 to 30 min of moderate intensity exercise using a variety of modalities. Heart rate will be monitored using Polar hear rate monitors (target intensity 40-70% heart rate reserve) and the BORG Rating of Perceived Exertion (12-15). Resistance exercise will target the large muscle groups of the upper and lower extremities, be performed at 40% to 70% of the one repetition maximum (1-RM) and consist of two sets of 10-15 repetitions. Flexibility and balance exercise will also be included in the twice weekly programme. A home exercise programme will encourage participants to be moderately physically active for at least 30 minutes, three times per week in addition to the supervised programme.
Study NCT01767480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RT
Description: The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
Study NCT01767480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation (CR)
Description: CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
Study NCT01767480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation (CR)
Description: CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
Study NCT00098501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pelitinib
Study NCT00098501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given PO
Study NCT01372423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 24 mcg capsules
Study NCT01372423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg capsules
Study NCT01372423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 mcg capsules
Study NCT03439423 — intervention group
Intervention type: RADIATION
Intervention: CT with contrast agent
Study NCT03439423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR without contrast agent
Description: on 1.5-T unit, with the following sequences:~* steady-state free-precession (true-FISP)~* half-Fourier single shot spin-echo (HASTE)
Study NCT03439423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Color-Doppler Ultrasound
Study NCT03439423 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: regarding their perception of examinations
Study NCT02533141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation
Study NCT02533141 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation
Study NCT02533141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler Velocimetry (LDV)
Description: Measurement of red blood cell velocity in retinal vessels
Study NCT02533141 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Doppler Velocimetry (LDV)
Description: Measurement of red blood cell velocity in retinal vessels
Study NCT02533141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
Study NCT02533141 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily for 4 weeks
Study NCT00961181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Releasing Balloon
Description: Percutaneous coronary intervention with paclitaxel releasing balloon
Study NCT01122160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
Study NCT01122160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo with berries (blackberries + strawberries)
Study NCT02345187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation
Description: The study product (fortified beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
Study NCT02345187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-fortified isocaloric beverage powder
Description: The study product (non-fortified isocaloric beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
Study NCT04375332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARPOON™ Beating Heart Mitral Valve Repair System
Description: Repair of the chordae tendinae in the mitral valve.
Study NCT01606709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: GnRH agonist 1mg one dose
Study NCT01606709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: 5,000 IU one dose
Study NCT01512134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation Device
Description: Deep brain stimulation surgery
Study NCT03837210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pylorin
Description: Poly Herbal formulation
Study NCT03837210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pylorin
Description: Poly Herbal formulation
Study NCT00215137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.
Study NCT00215137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.
Study NCT00215137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ( sugar pill)
Description: Placebo Comparator in double.blind phase.
Study NCT00283088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermia
Description: Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.~Subjects are stratified by time to six groups.
Study NCT00283088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator
Description: tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots
Study NCT02113345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metamemory Cognitive Intervention
Description: Metamemory Cognitive Intervention
Study NCT00969709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
Study NCT00969709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
Study NCT00969709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
Study NCT00969709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, oral administration, once daily for 8 weeks.
Study NCT01558401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: The activities are done in groups of no more than 25 individuals; these activities are standardized and agreed upon by the research team, which hold monthly meetings to conduct the study. Each physical activity session consists of 8-10 minutes of exercises aimed at stretching the major muscle groups (pectoral muscles, latissimus dorsi, cervical paravertebral, and posterior and anterior thigh muscles); 9 minutes of aerobic endurance activity (march/fast walk); 7-10 minutes of adapted strength exercises, power, and endurance training; 14-16 minutes of coordination, agility, and flexibility exercises, and 5-7 minutes of respiratory and relaxation exercises.
Study NCT02980731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
Study NCT01140698 — intervention group
Intervention type: OTHER
Intervention: Blood sample on Guthrie paper from cord blood, and day 3 of life and before discharge
Description: Mass spectroscopy on the blood sample that are taken as routine for the national inborn errors survey
Study NCT03143621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Brewed, caffeinated coffee, 100 cc's each dose
Study NCT03143621 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Tap water heated to same temperature as coffee
Study NCT02807662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Seeking Safety Intervention
Description: Intervention participants received Seeking Safety psychosocial education Intervention adapted for prenatal care setting.
Study NCT00591370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: One group treatment study
Study NCT04068766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paracervical block
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study NCT04068766 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Paracervical block
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study NCT04068766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% bupivacaine
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study NCT04068766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study NCT00833261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab
Study NCT00833261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin
Study NCT00833261 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: IMRT
Study NCT00833261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel